Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously ...

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials ...

Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...

Hollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 trial of ficerafusp alfa to treat ...

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

While this pembrolizumab-based regimen is promising and much needed in this patient population, one should remain cognizant of its high costs and the subsequent impact this may have on patients and ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

Findings from a phase 2 trial published in JTO Clinical and Research Reports suggest that pembrolizumab (Keytruda) plus ...

Mural Oncology (MURA) announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck’s (MRK) anti-PD-1 therapy, ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of ...